Founded in 1995, Nicast develops new vascular products, including artery grafts, and coated stents, based on new nano-scale manufacturing technology. TechnoPlus Ventures (TASE:TNPV) and Azritech Fund invested $2 million in Nicast in 2000.
Nicast's first product, a vascular implant, is in the advanced development stage. The implant acts like natural tissue and is accepted by the body, thus avoiding common transplant complications. Company sources have said in recent months that Nicast has been negotiating strategic agreements with leading companies.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments